Despite the large number of immunomodulatory or immunosuppressive treatments available
to treat relapsing–remitting multiple sclerosis (MS), treatment of the progressive phase of the …

Background B-cell depleting therapies are highly efficacious in relapsing-remitting multiple
sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no …

Multiple sclerosis (MS) is a common autoimmune disease that targets myelin in the central
nervous system (CNS). Multiple genome-wide association studies (GWAS) over the past 10 …

Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the
progressive loss of axonal myelin in several areas of the central nervous system (CNS) that …

Regulatory T (Treg) cells constitute a dynamic population that is essential for controlling
immune responses in health and disease. Defects in Treg cell function and decreases in …

Changes in gut microbiota composition and a diverse role of B cells have recently been
implicated in multiple sclerosis (MS), a central nervous system (CNS) autoimmune disease …

Monoclonal antibodies that target CD20 expressing B cells represent an important new
treatment option for patients with multiple sclerosis (MS). B‐cell‐depleting therapy is highly …

The pace of antibody therapeutics development accelerated in 2017, and this faster pace is
projected to continue through 2018. Notably, the annual number of antibody therapeutics …

Objective To assess dose-response effects of the anti-CD20 monoclonal antibody
ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing …

Abstract The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions
regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have …